{
    "name": "sumatriptan intranasal",
    "comment": "Rx",
    "other_names": [
        "Imitrex Intranasal",
        "Onzetra Xsail",
        "Tosymra"
    ],
    "classes": [
        "Serotonin 5-HT-Receptor Agonists",
        "Antimigraine Agents"
    ],
    "source": "https://reference.medscape.com/drug/imitrex-intranasal-onzetra-xsail-sumatriptan-intranasal-999812",
    "pregnancy": {
        "common": [
            "Data from prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected an increased frequency of birth defects or a consistent pattern of birth defects among women exposed to sumatriptan compared with the general population",
            "Several studies have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In developmental toxicity studies in rats and rabbits, oral administration to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality; when administered by intravenous route to pregnant rabbits, sumatriptan was embryo lethal"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "This drug is excreted in human milk following subcutaneous administration; there is no information regarding concentrations of this drug in milk from lactating women following administration of therapy",
            "There are no data on effects of sumatriptan on breastfed infant or effects of this drug on milk production",
            "The developmental and health benefits of breastfeeding should be considered along with mother's clinical need for this drug and any potential adverse effects on breastfed infants from sumatriptan or from underlying maternal condition",
            "Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with this drug"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Ischemic coronary artery disease (CAD) (eg, angina pectoris, history of myocardial infarction, or silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina or in patients with other significant underlying cardiovascular diseases",
                "Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders",
                "History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine",
                "Peripheral vascular disease",
                "Ischemic bowel",
                "Uncontrolled hypertension",
                "Recent use (eg, within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist",
                "Concurrent administration of an MAO-A inhibitor or recent use (within 2 weeks) of an MAO-A inhibitor",
                "Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen)",
                "Severe hepatic impairment"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Sensations of tightness, pain, pressure, and heaviness in chest, throat, neck, and jaw commonly occur after treatment with 5-HT1 agonists including other products containing sumatriptan and are usually non-cardiac in origin; however, perform a cardiac evaluation if these patients are at high cardiac risk; therapy is contraindicated in patients with known CAD and those with Prinzmetal’s variant angina",
                "Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension; monitor blood pressure in patients treated with this drug; therapy is contraindicated in patients with uncontrolled hypertension",
                "Hypersensitivity reactions, including angioedema and anaphylaxis, have occurred in patients receiving sumatriptan; such reactions can be life-threatening or fatal; in general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens; therapy is contraindicated in patients with history of hypersensitivity reaction to this drug",
                "Seizures reported following administration of therapy; some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures; there are also reports in patients where no such predisposing factors are apparent; this drug should be used with caution in patients with a history of epilepsy or conditions associated with a lowered seizure threshold"
            ],
            "specific": [
                {
                    "type": "Local irritation of nose and throat reported",
                    "description": [
                        "Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combinations of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache)",
                        "Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks",
                        "Detoxification of patients, including withdrawal of overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary"
                    ]
                },
                {
                    "type": "Medication Overuse Headache",
                    "description": [
                        "Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, reported within a few hours following administration of therapy ",
                        "Discontinue therapy if these disturbances occur; therapy is contraindicated in patients with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders"
                    ]
                },
                {
                    "type": "Arrhythmias",
                    "description": [
                        "There are rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of therapy; some occurred in patients without known CAD",
                        "5-HT1 agonists may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD",
                        "Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving therapy",
                        "If there is evidence of CAD or coronary artery vasospasm, therapy is contraindicated; for patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration",
                        "For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of the drug"
                    ]
                },
                {
                    "type": "Myocardial Ischemia, myocardial Infarction, and Prinzmetal’s angina",
                    "description": [
                        "Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have occurred in patients treated with 5-HT1 agonists including other products containing sumatriptan, and some have resulted in fatalities",
                        "In some cases, it appears possible that the cerebrovascular events were primary, the 5-HT1 agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not",
                        "Patients with migraine may be at increased risk of certain cerebrovascular events (eg, stroke, hemorrhage, TIA); therapy is contraindicated in patients with a history of stroke or TIA; discontinue therapy if a cerebrovascular event occurs",
                        "Before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, exclude other potentially serious neurological conditions"
                    ]
                },
                {
                    "type": "Cardiovascular events",
                    "description": [
                        "5-HT1 agonists may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction (presenting with abdominal pain and bloody diarrhea), splenic infarction, and Raynaud’s syndrome",
                        "In patients who experience symptoms or signs suggestive of a non-coronary vasospastic reaction following use of any 5-HT1 agonist, rule out a vasospastic reaction before using this drug",
                        "Transient and permanent blindness and significant partial vision loss have been reported with the use of 5-HT1 agonists including this drug",
                        "Since visual disorders may be part of a migraine attack, a causal relationship between these events and the use of 5-HT1 agonists have not been clearly established"
                    ]
                },
                {
                    "type": "Other vasospasm reactions",
                    "description": [
                        "Serotonin syndrome may occur with triptans, including this drug, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors",
                        "Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (eg, hyperreflexia, incoordination), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea)",
                        "The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication; discontinue therapy if serotonin syndrome is suspected"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "bromocriptine, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cabergoline",
            "description": {
                "common": "cabergoline, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dihydroergotamine intranasal, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "ergoloid mesylates, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ergotamine, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "methylergonovine, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "sumatriptan intranasal and procarbazine both increase  serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "rizatriptan, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "sumatriptan intranasal, zolmitriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram, sumatriptan intranasal. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "sumatriptan intranasal and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "sumatriptan intranasal and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dolasetron",
            "description": {
                "common": "dolasetron, sumatriptan intranasal.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron, sumatriptan intranasal.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "sumatriptan intranasal and isocarboxazid both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "sumatriptan intranasal and linezolid both increase  serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "sumatriptan intranasal and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylene blue",
            "description": {
                "common": "sumatriptan intranasal and methylene blue both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron, sumatriptan intranasal.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ondansetron",
            "description": {
                "common": "ondansetron, sumatriptan intranasal.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod increases toxicity of sumatriptan intranasal by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palonosetron",
            "description": {
                "common": "palonosetron, sumatriptan intranasal.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenelzine",
            "description": {
                "common": "sumatriptan intranasal and phenelzine both increase  serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tedizolid",
            "description": {
                "common": "tedizolid, sumatriptan intranasal.\nEither increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "sumatriptan intranasal and tranylcypromine both increase  serotonin levels. Avoid or Use Alternate Drug. Concomitant use or use within 2 wks following the discontinuation of tranylcypromine is contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilazodone",
            "description": {
                "common": "sumatriptan intranasal, vilazodone.\nEither increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "sumatriptan intranasal, vortioxetine.\nEither increases effects of the other by serotonin levels. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "5-HTP",
            "description": {
                "common": "sumatriptan intranasal and 5-HTP both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan and sumatriptan intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "sumatriptan intranasal and amitriptyline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "sumatriptan intranasal and amoxapine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "sumatriptan intranasal, aripiprazole. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "sumatriptan intranasal, asenapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen, sumatriptan intranasal.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buspirone",
            "description": {
                "common": "sumatriptan intranasal and buspirone both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cariprazine",
            "description": {
                "common": "sumatriptan intranasal, cariprazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "sumatriptan intranasal and clomipramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "sumatriptan intranasal, clozapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "sumatriptan intranasal and cocaine topical both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "cyproheptadine decreases effects of sumatriptan intranasal by pharmacodynamic antagonism. Use Caution/Monitor. Cyproheptadine may diminish the serotonergic effect of serotonin agonists."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "sumatriptan intranasal and desipramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "sumatriptan intranasal and dexfenfluramine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "sumatriptan intranasal and dextroamphetamine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "sumatriptan intranasal and dextromethorphan both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "sumatriptan intranasal and dihydroergotamine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "sumatriptan intranasal and dihydroergotamine intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "sumatriptan intranasal and dosulepin both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "sumatriptan intranasal and doxepin both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droxidopa",
            "description": {
                "common": "sumatriptan intranasal and droxidopa both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. May increase risk for supine hypertension"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "sumatriptan intranasal and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan and sumatriptan intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "sumatriptan intranasal and ergotamine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "sumatriptan intranasal and escitalopram both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "sumatriptan intranasal and fenfluramine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "sumatriptan intranasal and fluoxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "sumatriptan intranasal, fluphenazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine and sumatriptan intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan and sumatriptan intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "sumatriptan intranasal, haloperidol. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "hydrocodone, sumatriptan intranasal.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "sumatriptan intranasal, iloperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "sumatriptan intranasal and imipramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "sumatriptan intranasal and isoniazid both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "L-tryptophan",
            "description": {
                "common": "sumatriptan intranasal and L-tryptophan both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "sumatriptan intranasal and levodopa both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "sumatriptan intranasal and levomilnacipran both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "sumatriptan intranasal and lisdexamfetamine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "sumatriptan intranasal and lithium both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "sumatriptan intranasal and lofepramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "sumatriptan intranasal, loxapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "sumatriptan intranasal, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lsd",
            "description": {
                "common": "sumatriptan intranasal and lsd both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "sumatriptan intranasal, lurasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "sumatriptan intranasal and maprotiline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "sumatriptan intranasal and meperidine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "sumatriptan intranasal and milnacipran both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "sumatriptan intranasal and mirtazapine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "molindone",
            "description": {
                "common": "sumatriptan intranasal, molindone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "sumatriptan intranasal and morphine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan and sumatriptan intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "sumatriptan intranasal and nefazodone both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "sumatriptan intranasal and nortriptyline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "sumatriptan intranasal, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "sumatriptan intranasal, oliceridine.\nEither increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "sumatriptan intranasal, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "sumatriptan intranasal and paroxetine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "sumatriptan intranasal and pentazocine both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "sumatriptan intranasal, perphenazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "sumatriptan intranasal, pimavanserin. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "sumatriptan intranasal, pimozide. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "sumatriptan intranasal and protriptyline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "sumatriptan intranasal, quetiapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rasagiline",
            "description": {
                "common": "sumatriptan intranasal and rasagiline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remifentanil",
            "description": {
                "common": "remifentanil increases toxicity of sumatriptan intranasal by serotonin levels. Modify Therapy/Monitor Closely. Increases risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "sumatriptan intranasal, risperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "rizatriptan and sumatriptan intranasal both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "SAMe",
            "description": {
                "common": "sumatriptan intranasal and SAMe both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "sumatriptan intranasal and selegiline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "sumatriptan intranasal and selegiline transdermal both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sumatriptan intranasal and sertraline both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "sumatriptan intranasal and St John's Wort both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, sumatriptan intranasal.\nEither increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "sumatriptan intranasal and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "sumatriptan intranasal, thiothixene. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "sumatriptan intranasal and tramadol both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "sumatriptan intranasal and trazodone both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "sumatriptan intranasal, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "sumatriptan intranasal and trimipramine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "sumatriptan intranasal and venlafaxine both increase  serotonin levels. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "sumatriptan intranasal, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "sumatriptan intranasal and zolmitriptan both increase  serotonin levels. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "venlafaxine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Bad",
            "percent": "13.5-24.5"
        },
        {
            "name": "unusual taste",
            "percent": "11-13.5"
        },
        {
            "name": "Gastrointestinal",
            "percent": "2.5-3.8"
        },
        {
            "name": "nausea",
            "percent": "0.8-2.4"
        },
        {
            "name": "vomiting",
            "percent": "1-1.7"
        },
        {
            "name": "Disorder",
            "percent": "0.4-1.4"
        },
        {
            "name": "discomfort of nasal cavity",
            "percent": null
        },
        {
            "name": "sinuses",
            "percent": null
        },
        {
            "name": "Throat discomfort",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "vertigo",
            "percent": null
        },
        {
            "name": "Burning sensation",
            "percent": null
        },
        {
            "name": "Atypical Sensations",
            "percent": null
        },
        {
            "name": "Tingling",
            "percent": null
        },
        {
            "name": "numbness",
            "percent": null
        },
        {
            "name": "pressure sensation",
            "percent": null
        },
        {
            "name": "cold sensation",
            "percent": null
        },
        {
            "name": "feeling of tightness",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "hypertension",
            "percent": null
        },
        {
            "name": "palpations",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "arrhythmia",
            "percent": null
        },
        {
            "name": "edema",
            "percent": null
        },
        {
            "name": "Chest tightness",
            "percent": null
        },
        {
            "name": "discomfort",
            "percent": null
        },
        {
            "name": "chest pressure",
            "percent": null
        },
        {
            "name": "heaviness",
            "percent": null
        },
        {
            "name": "Disturbance of hearing",
            "percent": null
        },
        {
            "name": "ear infections",
            "percent": null
        },
        {
            "name": "Eye irritation and visual disturbances",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Abdominal discomfort",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "dysphagia",
            "percent": null
        },
        {
            "name": "GERD",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "thirst",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "Neck pain",
            "percent": null
        },
        {
            "name": "stiffness",
            "percent": null
        },
        {
            "name": "backache",
            "percent": null
        },
        {
            "name": "weakness",
            "percent": null
        },
        {
            "name": "joint symptoms",
            "percent": null
        },
        {
            "name": "arthritis",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "muscle cramps",
            "percent": null
        },
        {
            "name": "Neurological",
            "percent": null
        },
        {
            "name": "Drowsiness",
            "percent": null
        },
        {
            "name": "sedation",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "sleep disturbances",
            "percent": null
        },
        {
            "name": "tremors",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "confusion",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "lower respiratory infection",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "skin eruption",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "Urogenital",
            "percent": null
        },
        {
            "name": "Dysuria",
            "percent": null
        },
        {
            "name": "dysmenorrhea",
            "percent": null
        },
        {
            "name": "Blood",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Atrial fibrillation",
            "percent": null
        },
        {
            "name": "cardiomyopathy",
            "percent": null
        },
        {
            "name": "colonic ischemia",
            "percent": null
        },
        {
            "name": "Prinzmetal variant angina",
            "percent": null
        },
        {
            "name": "pulmonary embolism",
            "percent": null
        },
        {
            "name": "shock",
            "percent": null
        },
        {
            "name": "thrombophlebitis",
            "percent": null
        },
        {
            "name": "Ear",
            "percent": null
        },
        {
            "name": "nose",
            "percent": null
        },
        {
            "name": "throat",
            "percent": null
        },
        {
            "name": "Deafness",
            "percent": null
        },
        {
            "name": "Eye",
            "percent": null
        },
        {
            "name": "Ischemic optic neuropathy",
            "percent": null
        },
        {
            "name": "retinal artery occlusion",
            "percent": null
        },
        {
            "name": "retinal vein thrombosis",
            "percent": null
        },
        {
            "name": "loss of vision",
            "percent": null
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Ischemic colitis",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "Hepatic",
            "percent": null
        },
        {
            "name": "Elevated LFTs",
            "percent": null
        },
        {
            "name": "Neurological",
            "percent": null
        },
        {
            "name": "CNS vasculitis",
            "percent": null
        },
        {
            "name": "cerebrovascular accident",
            "percent": null
        },
        {
            "name": "dysphasia",
            "percent": null
        },
        {
            "name": "serotonin syndrome",
            "percent": null
        },
        {
            "name": "subarachnoid hemorrhage",
            "percent": null
        },
        {
            "name": "Psychiatric",
            "percent": null
        },
        {
            "name": "Panic disorder",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "bronchospasm in patients with or without a history of asthma",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "exacerbation of sunburn",
            "percent": null
        },
        {
            "name": "hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "photosensitivity",
            "percent": null
        },
        {
            "name": "Urogenital",
            "percent": null
        },
        {
            "name": "acute renal failure",
            "percent": null
        },
        {
            "name": "Nonspecific",
            "percent": null
        },
        {
            "name": "Angioneurotic edema",
            "percent": null
        },
        {
            "name": "cyanosis",
            "percent": null
        },
        {
            "name": "death",
            "percent": null
        },
        {
            "name": "temporal arteritis",
            "percent": null
        }
    ]
}